nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—EGFR—cervical cancer	0.536	1	CbGaD
Erlotinib—ABCG2—Topotecan—cervical cancer	0.149	0.634	CbGbCtD
Erlotinib—ABCB1—Topotecan—cervical cancer	0.0539	0.229	CbGbCtD
Erlotinib—CYP3A4—Topotecan—cervical cancer	0.0323	0.137	CbGbCtD
Erlotinib—Acute respiratory distress syndrome—Topotecan—cervical cancer	0.0066	0.121	CcSEcCtD
Erlotinib—Mucosal inflammation—Topotecan—cervical cancer	0.00311	0.0572	CcSEcCtD
Erlotinib—Interstitial lung disease—Topotecan—cervical cancer	0.00243	0.0447	CcSEcCtD
Erlotinib—Lung disorder—Topotecan—cervical cancer	0.00243	0.0447	CcSEcCtD
Erlotinib—Rigors—Topotecan—cervical cancer	0.00211	0.0388	CcSEcCtD
Erlotinib—Vandetanib—EGFR—cervical cancer	0.00195	0.513	CrCbGaD
Erlotinib—Gefitinib—EGFR—cervical cancer	0.00186	0.487	CrCbGaD
Erlotinib—HIPK4—female reproductive system—cervical cancer	0.00186	0.0169	CbGeAlD
Erlotinib—LTK—female reproductive system—cervical cancer	0.00183	0.0167	CbGeAlD
Erlotinib—Bone pain—Topotecan—cervical cancer	0.0018	0.033	CcSEcCtD
Erlotinib—TNK1—uterine cervix—cervical cancer	0.0018	0.0163	CbGeAlD
Erlotinib—TNK1—decidua—cervical cancer	0.00171	0.0156	CbGeAlD
Erlotinib—Colitis—Topotecan—cervical cancer	0.00165	0.0304	CcSEcCtD
Erlotinib—TNK1—endometrium—cervical cancer	0.00163	0.0148	CbGeAlD
Erlotinib—Neuropathy—Topotecan—cervical cancer	0.00162	0.0297	CcSEcCtD
Erlotinib—AURKC—female reproductive system—cervical cancer	0.00158	0.0144	CbGeAlD
Erlotinib—TNK1—mammalian vulva—cervical cancer	0.00157	0.0143	CbGeAlD
Erlotinib—TNK1—uterus—cervical cancer	0.0015	0.0136	CbGeAlD
Erlotinib—Sepsis—Topotecan—cervical cancer	0.00149	0.0275	CcSEcCtD
Erlotinib—JAK3—female reproductive system—cervical cancer	0.00147	0.0133	CbGeAlD
Erlotinib—EPHA6—female reproductive system—cervical cancer	0.00147	0.0133	CbGeAlD
Erlotinib—EGFR—uterine cervix—cervical cancer	0.00144	0.0131	CbGeAlD
Erlotinib—PIP4K2C—uterine cervix—cervical cancer	0.0014	0.0127	CbGeAlD
Erlotinib—JAK3—female gonad—cervical cancer	0.00133	0.0121	CbGeAlD
Erlotinib—MAP3K19—female reproductive system—cervical cancer	0.00133	0.0121	CbGeAlD
Erlotinib—ULK3—uterine cervix—cervical cancer	0.00133	0.0121	CbGeAlD
Erlotinib—PIP4K2C—decidua—cervical cancer	0.00133	0.0121	CbGeAlD
Erlotinib—Dermatitis bullous—Topotecan—cervical cancer	0.00131	0.024	CcSEcCtD
Erlotinib—ULK3—decidua—cervical cancer	0.00127	0.0115	CbGeAlD
Erlotinib—PIP4K2C—endometrium—cervical cancer	0.00126	0.0115	CbGeAlD
Erlotinib—EGFR—mammalian vulva—cervical cancer	0.00126	0.0114	CbGeAlD
Erlotinib—MKNK1—uterine cervix—cervical cancer	0.00125	0.0114	CbGeAlD
Erlotinib—TNK1—female gonad—cervical cancer	0.00123	0.0111	CbGeAlD
Erlotinib—PIP4K2C—mammalian vulva—cervical cancer	0.00122	0.0111	CbGeAlD
Erlotinib—TNK1—vagina—cervical cancer	0.00122	0.0111	CbGeAlD
Erlotinib—ULK3—endometrium—cervical cancer	0.0012	0.0109	CbGeAlD
Erlotinib—EGFR—uterus—cervical cancer	0.0012	0.0109	CbGeAlD
Erlotinib—MKNK1—decidua—cervical cancer	0.00119	0.0109	CbGeAlD
Erlotinib—SLK—uterine cervix—cervical cancer	0.00119	0.0108	CbGeAlD
Erlotinib—ULK3—mammalian vulva—cervical cancer	0.00117	0.0106	CbGeAlD
Erlotinib—FLT3—female reproductive system—cervical cancer	0.00116	0.0105	CbGeAlD
Erlotinib—MKNK1—endometrium—cervical cancer	0.00113	0.0103	CbGeAlD
Erlotinib—SLK—decidua—cervical cancer	0.00113	0.0103	CbGeAlD
Erlotinib—ULK3—uterus—cervical cancer	0.00111	0.0101	CbGeAlD
Erlotinib—Alanine aminotransferase increased—Topotecan—cervical cancer	0.0011	0.0203	CcSEcCtD
Erlotinib—MKNK1—mammalian vulva—cervical cancer	0.0011	0.00997	CbGeAlD
Erlotinib—SLK—endometrium—cervical cancer	0.00107	0.00976	CbGeAlD
Erlotinib—LTK—lymph node—cervical cancer	0.00107	0.00975	CbGeAlD
Erlotinib—FLT3—female gonad—cervical cancer	0.00105	0.00957	CbGeAlD
Erlotinib—PIP4K2C—female reproductive system—cervical cancer	0.00105	0.0095	CbGeAlD
Erlotinib—SLK—mammalian vulva—cervical cancer	0.00104	0.00944	CbGeAlD
Erlotinib—STK10—uterine cervix—cervical cancer	0.00103	0.00938	CbGeAlD
Erlotinib—Neutropenia—Topotecan—cervical cancer	0.00101	0.0186	CcSEcCtD
Erlotinib—ABL2—female gonad—cervical cancer	0.00101	0.00914	CbGeAlD
Erlotinib—ABL2—vagina—cervical cancer	0.000999	0.00908	CbGeAlD
Erlotinib—ULK3—female reproductive system—cervical cancer	0.000998	0.00907	CbGeAlD
Erlotinib—SLK—uterus—cervical cancer	0.00099	0.00899	CbGeAlD
Erlotinib—STK10—decidua—cervical cancer	0.000984	0.00894	CbGeAlD
Erlotinib—EGFR—female gonad—cervical cancer	0.000981	0.00892	CbGeAlD
Erlotinib—Pneumonia—Topotecan—cervical cancer	0.000969	0.0178	CcSEcCtD
Erlotinib—STK10—renal system—cervical cancer	0.000966	0.00878	CbGeAlD
Erlotinib—Infestation NOS—Topotecan—cervical cancer	0.000963	0.0177	CcSEcCtD
Erlotinib—Infestation—Topotecan—cervical cancer	0.000963	0.0177	CcSEcCtD
Erlotinib—PIP4K2C—female gonad—cervical cancer	0.000951	0.00864	CbGeAlD
Erlotinib—PIP4K2C—vagina—cervical cancer	0.000945	0.00859	CbGeAlD
Erlotinib—Neuropathy peripheral—Topotecan—cervical cancer	0.000944	0.0174	CcSEcCtD
Erlotinib—MKNK1—female reproductive system—cervical cancer	0.000939	0.00854	CbGeAlD
Erlotinib—Stomatitis—Topotecan—cervical cancer	0.000939	0.0173	CcSEcCtD
Erlotinib—AURKC—lymph node—cervical cancer	0.000927	0.00842	CbGeAlD
Erlotinib—MAP2K5—uterine cervix—cervical cancer	0.000922	0.00838	CbGeAlD
Erlotinib—UGT1A1—renal system—cervical cancer	0.000912	0.00829	CbGeAlD
Erlotinib—Hepatobiliary disease—Topotecan—cervical cancer	0.000911	0.0167	CcSEcCtD
Erlotinib—Epistaxis—Topotecan—cervical cancer	0.000909	0.0167	CcSEcCtD
Erlotinib—ULK3—female gonad—cervical cancer	0.000908	0.00825	CbGeAlD
Erlotinib—STK10—mammalian vulva—cervical cancer	0.000903	0.00821	CbGeAlD
Erlotinib—ULK3—vagina—cervical cancer	0.000903	0.0082	CbGeAlD
Erlotinib—MAP2K5—decidua—cervical cancer	0.000878	0.00798	CbGeAlD
Erlotinib—Haemoglobin—Topotecan—cervical cancer	0.000869	0.016	CcSEcCtD
Erlotinib—Haemorrhage—Topotecan—cervical cancer	0.000865	0.0159	CcSEcCtD
Erlotinib—STK10—uterus—cervical cancer	0.00086	0.00782	CbGeAlD
Erlotinib—JAK3—lymph node—cervical cancer	0.000858	0.0078	CbGeAlD
Erlotinib—MKNK1—female gonad—cervical cancer	0.000855	0.00777	CbGeAlD
Erlotinib—MKNK1—vagina—cervical cancer	0.00085	0.00772	CbGeAlD
Erlotinib—MAP2K5—endometrium—cervical cancer	0.000834	0.00758	CbGeAlD
Erlotinib—SLK—female gonad—cervical cancer	0.000809	0.00736	CbGeAlD
Erlotinib—MAP2K5—mammalian vulva—cervical cancer	0.000807	0.00733	CbGeAlD
Erlotinib—SLK—vagina—cervical cancer	0.000804	0.00731	CbGeAlD
Erlotinib—TNK1—lymph node—cervical cancer	0.000788	0.00716	CbGeAlD
Erlotinib—Mediastinal disorder—Topotecan—cervical cancer	0.000779	0.0143	CcSEcCtD
Erlotinib—Chills—Topotecan—cervical cancer	0.000776	0.0143	CcSEcCtD
Erlotinib—STK10—female reproductive system—cervical cancer	0.000774	0.00703	CbGeAlD
Erlotinib—Alopecia—Topotecan—cervical cancer	0.000764	0.014	CcSEcCtD
Erlotinib—Malnutrition—Topotecan—cervical cancer	0.000753	0.0138	CcSEcCtD
Erlotinib—Back pain—Topotecan—cervical cancer	0.000728	0.0134	CcSEcCtD
Erlotinib—ABL1—uterine cervix—cervical cancer	0.000711	0.00646	CbGeAlD
Erlotinib—STK10—female gonad—cervical cancer	0.000704	0.0064	CbGeAlD
Erlotinib—STK10—vagina—cervical cancer	0.0007	0.00636	CbGeAlD
Erlotinib—MAP2K5—female reproductive system—cervical cancer	0.000691	0.00628	CbGeAlD
Erlotinib—SLCO2B1—decidua—cervical cancer	0.000684	0.00621	CbGeAlD
Erlotinib—ABL1—decidua—cervical cancer	0.000678	0.00616	CbGeAlD
Erlotinib—ORM1—endometrium—cervical cancer	0.000677	0.00615	CbGeAlD
Erlotinib—FLT3—lymph node—cervical cancer	0.000677	0.00615	CbGeAlD
Erlotinib—SLCO2B1—renal system—cervical cancer	0.000671	0.0061	CbGeAlD
Erlotinib—ABL1—renal system—cervical cancer	0.000665	0.00605	CbGeAlD
Erlotinib—Cough—Topotecan—cervical cancer	0.000657	0.0121	CcSEcCtD
Erlotinib—ABL2—lymph node—cervical cancer	0.000646	0.00587	CbGeAlD
Erlotinib—ABL1—endometrium—cervical cancer	0.000643	0.00585	CbGeAlD
Erlotinib—Arthralgia—Topotecan—cervical cancer	0.000641	0.0118	CcSEcCtD
Erlotinib—Myalgia—Topotecan—cervical cancer	0.000641	0.0118	CcSEcCtD
Erlotinib—Chest pain—Topotecan—cervical cancer	0.000641	0.0118	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.000636	0.0117	CcSEcCtD
Erlotinib—EGFR—lymph node—cervical cancer	0.000631	0.00573	CbGeAlD
Erlotinib—MAP2K5—female gonad—cervical cancer	0.000629	0.00571	CbGeAlD
Erlotinib—MAP2K5—vagina—cervical cancer	0.000625	0.00568	CbGeAlD
Erlotinib—ABL1—mammalian vulva—cervical cancer	0.000622	0.00566	CbGeAlD
Erlotinib—PIP4K2C—lymph node—cervical cancer	0.000611	0.00556	CbGeAlD
Erlotinib—Infection—Topotecan—cervical cancer	0.00061	0.0112	CcSEcCtD
Erlotinib—Nervous system disorder—Topotecan—cervical cancer	0.000602	0.0111	CcSEcCtD
Erlotinib—Thrombocytopenia—Topotecan—cervical cancer	0.000602	0.0111	CcSEcCtD
Erlotinib—SLCO2B1—uterus—cervical cancer	0.000598	0.00543	CbGeAlD
Erlotinib—Skin disorder—Topotecan—cervical cancer	0.000597	0.011	CcSEcCtD
Erlotinib—ABL1—uterus—cervical cancer	0.000593	0.00539	CbGeAlD
Erlotinib—Anorexia—Topotecan—cervical cancer	0.000586	0.0108	CcSEcCtD
Erlotinib—ULK3—lymph node—cervical cancer	0.000584	0.00531	CbGeAlD
Erlotinib—CYP1B1—decidua—cervical cancer	0.000574	0.00522	CbGeAlD
Erlotinib—CYP1B1—renal system—cervical cancer	0.000563	0.00512	CbGeAlD
Erlotinib—ORM1—female reproductive system—cervical cancer	0.000561	0.0051	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00056	0.0103	CcSEcCtD
Erlotinib—MKNK1—lymph node—cervical cancer	0.000549	0.00499	CbGeAlD
Erlotinib—Dyspnoea—Topotecan—cervical cancer	0.000548	0.0101	CcSEcCtD
Erlotinib—Dyspepsia—Topotecan—cervical cancer	0.000541	0.00994	CcSEcCtD
Erlotinib—SLCO2B1—female reproductive system—cervical cancer	0.000538	0.00489	CbGeAlD
Erlotinib—Decreased appetite—Topotecan—cervical cancer	0.000534	0.00982	CcSEcCtD
Erlotinib—ABL1—female reproductive system—cervical cancer	0.000533	0.00484	CbGeAlD
Erlotinib—Gastrointestinal disorder—Topotecan—cervical cancer	0.00053	0.00975	CcSEcCtD
Erlotinib—Fatigue—Topotecan—cervical cancer	0.00053	0.00974	CcSEcCtD
Erlotinib—Pain—Topotecan—cervical cancer	0.000525	0.00966	CcSEcCtD
Erlotinib—Constipation—Topotecan—cervical cancer	0.000525	0.00966	CcSEcCtD
Erlotinib—SLK—lymph node—cervical cancer	0.00052	0.00473	CbGeAlD
Erlotinib—Gastrointestinal pain—Topotecan—cervical cancer	0.000502	0.00924	CcSEcCtD
Erlotinib—CYP1B1—uterus—cervical cancer	0.000502	0.00456	CbGeAlD
Erlotinib—SLCO2B1—female gonad—cervical cancer	0.000489	0.00445	CbGeAlD
Erlotinib—Body temperature increased—Topotecan—cervical cancer	0.000486	0.00893	CcSEcCtD
Erlotinib—Abdominal pain—Topotecan—cervical cancer	0.000486	0.00893	CcSEcCtD
Erlotinib—ABL1—female gonad—cervical cancer	0.000485	0.00441	CbGeAlD
Erlotinib—ABL1—vagina—cervical cancer	0.000482	0.00438	CbGeAlD
Erlotinib—STK10—lymph node—cervical cancer	0.000452	0.00411	CbGeAlD
Erlotinib—CYP1B1—female reproductive system—cervical cancer	0.000451	0.0041	CbGeAlD
Erlotinib—ABCG2—uterine cervix—cervical cancer	0.000449	0.00408	CbGeAlD
Erlotinib—Asthenia—Topotecan—cervical cancer	0.000441	0.0081	CcSEcCtD
Erlotinib—Pruritus—Topotecan—cervical cancer	0.000435	0.00799	CcSEcCtD
Erlotinib—CYP2C8—renal system—cervical cancer	0.000432	0.00392	CbGeAlD
Erlotinib—CYP1A1—epithelium—cervical cancer	0.000429	0.0039	CbGeAlD
Erlotinib—ABCG2—decidua—cervical cancer	0.000427	0.00388	CbGeAlD
Erlotinib—CYP1A1—uterine cervix—cervical cancer	0.000426	0.00387	CbGeAlD
Erlotinib—Diarrhoea—Topotecan—cervical cancer	0.00042	0.00773	CcSEcCtD
Erlotinib—CYP2C8—endometrium—cervical cancer	0.000417	0.00379	CbGeAlD
Erlotinib—CYP3A5—uterine cervix—cervical cancer	0.000416	0.00378	CbGeAlD
Erlotinib—CYP1B1—female gonad—cervical cancer	0.000411	0.00373	CbGeAlD
Erlotinib—Dizziness—Topotecan—cervical cancer	0.000406	0.00747	CcSEcCtD
Erlotinib—ABCG2—endometrium—cervical cancer	0.000406	0.00369	CbGeAlD
Erlotinib—MAP2K5—lymph node—cervical cancer	0.000404	0.00367	CbGeAlD
Erlotinib—CYP1A2—renal system—cervical cancer	0.000404	0.00367	CbGeAlD
Erlotinib—CYP1A1—renal system—cervical cancer	0.000398	0.00362	CbGeAlD
Erlotinib—ABCG2—mammalian vulva—cervical cancer	0.000392	0.00357	CbGeAlD
Erlotinib—Vomiting—Topotecan—cervical cancer	0.000391	0.00718	CcSEcCtD
Erlotinib—CYP3A5—renal system—cervical cancer	0.000389	0.00354	CbGeAlD
Erlotinib—Rash—Topotecan—cervical cancer	0.000387	0.00712	CcSEcCtD
Erlotinib—Dermatitis—Topotecan—cervical cancer	0.000387	0.00712	CcSEcCtD
Erlotinib—Headache—Topotecan—cervical cancer	0.000385	0.00708	CcSEcCtD
Erlotinib—ABCG2—uterus—cervical cancer	0.000374	0.0034	CbGeAlD
Erlotinib—CYP1A1—mammalian vulva—cervical cancer	0.000373	0.00339	CbGeAlD
Erlotinib—Nausea—Topotecan—cervical cancer	0.000365	0.00671	CcSEcCtD
Erlotinib—CYP1A1—uterus—cervical cancer	0.000355	0.00323	CbGeAlD
Erlotinib—CYP2C8—female reproductive system—cervical cancer	0.000346	0.00314	CbGeAlD
Erlotinib—ORM1—lymph node—cervical cancer	0.000328	0.00298	CbGeAlD
Erlotinib—CYP1A1—female reproductive system—cervical cancer	0.000319	0.0029	CbGeAlD
Erlotinib—SLCO2B1—lymph node—cervical cancer	0.000314	0.00286	CbGeAlD
Erlotinib—CYP2C8—vagina—cervical cancer	0.000313	0.00284	CbGeAlD
Erlotinib—ABL1—lymph node—cervical cancer	0.000312	0.00283	CbGeAlD
Erlotinib—ABCG2—female gonad—cervical cancer	0.000306	0.00278	CbGeAlD
Erlotinib—ABCG2—vagina—cervical cancer	0.000304	0.00276	CbGeAlD
Erlotinib—CYP3A4—renal system—cervical cancer	0.000292	0.00266	CbGeAlD
Erlotinib—CYP1A1—female gonad—cervical cancer	0.00029	0.00264	CbGeAlD
Erlotinib—CYP1A1—vagina—cervical cancer	0.000289	0.00262	CbGeAlD
Erlotinib—ALB—lymph node—cervical cancer	0.000288	0.00261	CbGeAlD
Erlotinib—CYP2D6—renal system—cervical cancer	0.000288	0.00261	CbGeAlD
Erlotinib—CYP3A5—female gonad—cervical cancer	0.000284	0.00258	CbGeAlD
Erlotinib—CYP3A5—vagina—cervical cancer	0.000282	0.00256	CbGeAlD
Erlotinib—CYP1B1—lymph node—cervical cancer	0.000264	0.0024	CbGeAlD
Erlotinib—CYP3A4—female reproductive system—cervical cancer	0.000234	0.00213	CbGeAlD
Erlotinib—CYP2D6—female reproductive system—cervical cancer	0.00023	0.00209	CbGeAlD
Erlotinib—ABCB1—epithelium—cervical cancer	0.000223	0.00203	CbGeAlD
Erlotinib—ABCB1—uterine cervix—cervical cancer	0.000221	0.00201	CbGeAlD
Erlotinib—ABCB1—decidua—cervical cancer	0.000211	0.00192	CbGeAlD
Erlotinib—CYP2D6—female gonad—cervical cancer	0.00021	0.0019	CbGeAlD
Erlotinib—ABCB1—renal system—cervical cancer	0.000207	0.00188	CbGeAlD
Erlotinib—ABCB1—endometrium—cervical cancer	0.0002	0.00182	CbGeAlD
Erlotinib—ABCG2—lymph node—cervical cancer	0.000197	0.00179	CbGeAlD
Erlotinib—ABCB1—mammalian vulva—cervical cancer	0.000193	0.00176	CbGeAlD
Erlotinib—CYP1A1—lymph node—cervical cancer	0.000187	0.0017	CbGeAlD
Erlotinib—ABCB1—uterus—cervical cancer	0.000184	0.00168	CbGeAlD
Erlotinib—ABCB1—female reproductive system—cervical cancer	0.000166	0.00151	CbGeAlD
Erlotinib—ABCB1—female gonad—cervical cancer	0.000151	0.00137	CbGeAlD
Erlotinib—ABCB1—vagina—cervical cancer	0.00015	0.00136	CbGeAlD
Erlotinib—ABCB1—lymph node—cervical cancer	9.69e-05	0.000881	CbGeAlD
Erlotinib—ABL2—Developmental Biology—CTNNB1—cervical cancer	6.09e-05	0.00101	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—TAAR6—cervical cancer	6.06e-05	0.00101	CbGpPWpGaD
Erlotinib—EGFR—Rac1/Pak1/p38/MMP-2 pathway—TP53—cervical cancer	6.04e-05	0.001	CbGpPWpGaD
Erlotinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	6.01e-05	0.000999	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—CASP3—cervical cancer	5.99e-05	0.000996	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—MTOR—cervical cancer	5.98e-05	0.000994	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—CASP8—cervical cancer	5.97e-05	0.000992	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—FGFR3—cervical cancer	5.93e-05	0.000986	CbGpPWpGaD
Erlotinib—ABL1—EGF/EGFR Signaling Pathway—MTOR—cervical cancer	5.92e-05	0.000984	CbGpPWpGaD
Erlotinib—MAP2K5—Focal Adhesion—EGFR—cervical cancer	5.83e-05	0.000969	CbGpPWpGaD
Erlotinib—JAK3—Immune System—HLA-DPB1—cervical cancer	5.81e-05	0.000966	CbGpPWpGaD
Erlotinib—JAK3—Cytokine Signaling in Immune system—STAT3—cervical cancer	5.77e-05	0.000959	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—CASP3—cervical cancer	5.76e-05	0.000957	CbGpPWpGaD
Erlotinib—ABL1—Retinoblastoma (RB) in Cancer—TP53—cervical cancer	5.74e-05	0.000954	CbGpPWpGaD
Erlotinib—EPHA6—Axon guidance—EGFR—cervical cancer	5.7e-05	0.000948	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—MTOR—cervical cancer	5.65e-05	0.000939	CbGpPWpGaD
Erlotinib—ABL1—PDGFR-beta signaling pathway—STAT3—cervical cancer	5.63e-05	0.000935	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKAP13—cervical cancer	5.61e-05	0.000932	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—CTNNB1—cervical cancer	5.55e-05	0.000923	CbGpPWpGaD
Erlotinib—EGFR—ErbB1 downstream signaling—STAT3—cervical cancer	5.53e-05	0.000919	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—CASP8—cervical cancer	5.51e-05	0.000916	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—CASP3—cervical cancer	5.5e-05	0.000914	CbGpPWpGaD
Erlotinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—EGFR—cervical cancer	5.46e-05	0.000908	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—MTOR—cervical cancer	5.41e-05	0.000899	CbGpPWpGaD
Erlotinib—MAP2K5—MAPK Signaling Pathway—TP53—cervical cancer	5.4e-05	0.000897	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	5.39e-05	0.000896	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—MTOR—cervical cancer	5.35e-05	0.000889	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—MTOR—cervical cancer	5.32e-05	0.000885	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—STAT3—cervical cancer	5.31e-05	0.000883	CbGpPWpGaD
Erlotinib—MKNK1—Disease—HES1—cervical cancer	5.28e-05	0.000877	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—WNT2—cervical cancer	5.21e-05	0.000866	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways in Glioblastoma—TP53—cervical cancer	5.14e-05	0.000855	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—CTNNB1—cervical cancer	5.14e-05	0.000854	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—MTOR—cervical cancer	5.08e-05	0.000845	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—MTOR—cervical cancer	5.06e-05	0.000841	CbGpPWpGaD
Erlotinib—EGFR—EGF/EGFR Signaling Pathway—MTOR—cervical cancer	5.06e-05	0.000841	CbGpPWpGaD
Erlotinib—ABL1—Cell Cycle—TP53—cervical cancer	5.05e-05	0.00084	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—MTOR—cervical cancer	5.03e-05	0.000836	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—MTOR—cervical cancer	5.01e-05	0.000832	CbGpPWpGaD
Erlotinib—ABL1—Immune System—UBE3A—cervical cancer	4.98e-05	0.000828	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—MTOR—cervical cancer	4.94e-05	0.00082	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—CASP3—cervical cancer	4.92e-05	0.000818	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—WNT5A—cervical cancer	4.84e-05	0.000805	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—EGFR—cervical cancer	4.83e-05	0.000802	CbGpPWpGaD
Erlotinib—ABL1—DNA Damage Response (only ATM dependent)—TP53—cervical cancer	4.79e-05	0.000797	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	4.77e-05	0.000793	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—CTNNB1—cervical cancer	4.74e-05	0.000788	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—WNT2—cervical cancer	4.73e-05	0.000786	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—MTOR—cervical cancer	4.71e-05	0.000783	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—MTOR—cervical cancer	4.71e-05	0.000783	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—MTOR—cervical cancer	4.71e-05	0.000783	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—MTOR—cervical cancer	4.67e-05	0.000776	CbGpPWpGaD
Erlotinib—MKNK1—Disease—MTHFR—cervical cancer	4.64e-05	0.00077	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—MTOR—cervical cancer	4.63e-05	0.000769	CbGpPWpGaD
Erlotinib—MKNK1—Disease—TERT—cervical cancer	4.62e-05	0.000768	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—STAT3—cervical cancer	4.62e-05	0.000768	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—MTOR—cervical cancer	4.61e-05	0.000766	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	4.6e-05	0.000765	CbGpPWpGaD
Erlotinib—ABL1—EGF/EGFR Signaling Pathway—STAT3—cervical cancer	4.57e-05	0.00076	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKAP13—cervical cancer	4.57e-05	0.00076	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—FGFR3—cervical cancer	4.56e-05	0.000758	CbGpPWpGaD
Erlotinib—JAK3—Immune System—HLA-DQB1—cervical cancer	4.54e-05	0.000754	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—CASP3—cervical cancer	4.52e-05	0.000751	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—NOTCH2—cervical cancer	4.51e-05	0.000749	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—STAT3—cervical cancer	4.48e-05	0.000744	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—EGFR—cervical cancer	4.4e-05	0.000731	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—STAT3—cervical cancer	4.37e-05	0.000726	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—MTOR—cervical cancer	4.36e-05	0.000725	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—HES1—cervical cancer	4.29e-05	0.000713	CbGpPWpGaD
Erlotinib—EGFR—Immune System—UBE3A—cervical cancer	4.26e-05	0.000708	CbGpPWpGaD
Erlotinib—MKNK1—Disease—FGFR3—cervical cancer	4.24e-05	0.000705	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CD8A—cervical cancer	4.24e-05	0.000704	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—EGFR—cervical cancer	4.2e-05	0.000698	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HLA-DPB1—cervical cancer	4.19e-05	0.000697	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—MTOR—cervical cancer	4.17e-05	0.000694	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—CASP3—cervical cancer	4.17e-05	0.000693	CbGpPWpGaD
Erlotinib—ABL1—EGF/EGFR Signaling Pathway—EGFR—cervical cancer	4.16e-05	0.000691	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKAP13—cervical cancer	4.15e-05	0.00069	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	4.08e-05	0.000678	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—EGFR—cervical cancer	4.07e-05	0.000676	CbGpPWpGaD
Erlotinib—ABL1—Factors involved in megakaryocyte development and platelet production—TP53—cervical cancer	4.01e-05	0.000667	CbGpPWpGaD
Erlotinib—EGFR—Disease—WNT2—cervical cancer	3.99e-05	0.000663	CbGpPWpGaD
Erlotinib—MKNK1—Disease—NOTCH1—cervical cancer	3.98e-05	0.000662	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—CTNNB1—cervical cancer	3.95e-05	0.000656	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—WNT5A—cervical cancer	3.95e-05	0.000656	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	3.93e-05	0.000653	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—STAT3—cervical cancer	3.93e-05	0.000653	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—cervical cancer	3.92e-05	0.000651	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—cervical cancer	3.92e-05	0.000651	CbGpPWpGaD
Erlotinib—EGFR—EGF/EGFR Signaling Pathway—STAT3—cervical cancer	3.91e-05	0.00065	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—TP53—cervical cancer	3.84e-05	0.000639	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—NOTCH1—cervical cancer	3.8e-05	0.000632	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HES1—cervical cancer	3.69e-05	0.000614	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—TP53—cervical cancer	3.69e-05	0.000614	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—HES1—cervical cancer	3.66e-05	0.000609	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	3.64e-05	0.000606	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—STAT3—cervical cancer	3.64e-05	0.000605	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—WNT5A—cervical cancer	3.58e-05	0.000596	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TAAR6—cervical cancer	3.58e-05	0.000595	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—STAT3—cervical cancer	3.56e-05	0.000592	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—TP53—cervical cancer	3.52e-05	0.000586	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CA9—cervical cancer	3.47e-05	0.000577	CbGpPWpGaD
Erlotinib—JAK3—Immune System—FGFR3—cervical cancer	3.46e-05	0.000576	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NOTCH2—cervical cancer	3.4e-05	0.000565	CbGpPWpGaD
Erlotinib—EGFR—Direct p53 effectors—TP53—cervical cancer	3.35e-05	0.000557	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HLA-DQB1—cervical cancer	3.27e-05	0.000544	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CA9—cervical cancer	3.24e-05	0.000538	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—NOTCH1—cervical cancer	3.24e-05	0.000538	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TERT—cervical cancer	3.24e-05	0.000538	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	3.22e-05	0.000536	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—MTOR—cervical cancer	3.21e-05	0.000533	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—TP53—cervical cancer	3.16e-05	0.000524	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	3.06e-05	0.000509	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD8A—cervical cancer	3.05e-05	0.000508	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—FGFR3—cervical cancer	3.05e-05	0.000506	CbGpPWpGaD
Erlotinib—EGFR—Disease—WNT5A—cervical cancer	3.02e-05	0.000503	CbGpPWpGaD
Erlotinib—MKNK1—Disease—MTOR—cervical cancer	2.98e-05	0.000496	CbGpPWpGaD
Erlotinib—MKNK1—Disease—CD4—cervical cancer	2.98e-05	0.000495	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HLA-DPB1—cervical cancer	2.97e-05	0.000494	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—FGFR3—cervical cancer	2.97e-05	0.000494	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CASP8—cervical cancer	2.96e-05	0.000492	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—CASP3—cervical cancer	2.95e-05	0.000491	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CA9—cervical cancer	2.95e-05	0.00049	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—TP53—cervical cancer	2.9e-05	0.000482	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—WNT2—cervical cancer	2.79e-05	0.000464	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—NOTCH1—cervical cancer	2.79e-05	0.000464	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HES1—cervical cancer	2.79e-05	0.000463	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NOTCH2—cervical cancer	2.77e-05	0.00046	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—NOTCH1—cervical cancer	2.77e-05	0.00046	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—TP53—cervical cancer	2.74e-05	0.000456	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	2.72e-05	0.000452	CbGpPWpGaD
Erlotinib—MKNK1—Disease—CTNNB1—cervical cancer	2.65e-05	0.00044	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	2.61e-05	0.000435	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CASP8—cervical cancer	2.6e-05	0.000433	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—FGFR3—cervical cancer	2.6e-05	0.000433	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HLA-DPB1—cervical cancer	2.54e-05	0.000423	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—FGFR3—cervical cancer	2.5e-05	0.000415	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—STAT3—cervical cancer	2.48e-05	0.000412	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKAP13—cervical cancer	2.45e-05	0.000408	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TERT—cervical cancer	2.44e-05	0.000406	CbGpPWpGaD
Erlotinib—JAK3—Immune System—MTOR—cervical cancer	2.44e-05	0.000405	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CD4—cervical cancer	2.43e-05	0.000404	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—EGFR—cervical cancer	2.39e-05	0.000397	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HLA-DQB1—cervical cancer	2.32e-05	0.000386	CbGpPWpGaD
Erlotinib—MKNK1—Disease—STAT3—cervical cancer	2.31e-05	0.000383	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HES1—cervical cancer	2.27e-05	0.000377	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FGFR3—cervical cancer	2.24e-05	0.000372	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CASP8—cervical cancer	2.23e-05	0.00037	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD8A—cervical cancer	2.17e-05	0.00036	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CTNNB1—cervical cancer	2.16e-05	0.000359	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—CTNNB1—cervical cancer	2.15e-05	0.000357	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—MTOR—cervical cancer	2.14e-05	0.000356	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CD4—cervical cancer	2.14e-05	0.000355	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—WNT5A—cervical cancer	2.12e-05	0.000352	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CA9—cervical cancer	2.11e-05	0.000351	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NOTCH1—cervical cancer	2.1e-05	0.00035	CbGpPWpGaD
Erlotinib—MKNK1—Disease—EGFR—cervical cancer	2.1e-05	0.000348	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MTOR—cervical cancer	2.09e-05	0.000347	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	2.06e-05	0.000342	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CA9—cervical cancer	1.99e-05	0.000331	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TERT—cervical cancer	1.99e-05	0.000331	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HLA-DQB1—cervical cancer	1.98e-05	0.00033	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	1.98e-05	0.00033	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CASP3—cervical cancer	1.92e-05	0.000319	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CTNNB1—cervical cancer	1.9e-05	0.000316	CbGpPWpGaD
Erlotinib—JAK3—Immune System—STAT3—cervical cancer	1.88e-05	0.000313	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—STAT3—cervical cancer	1.87e-05	0.000312	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—EGFR—cervical cancer	1.87e-05	0.000311	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD8A—cervical cancer	1.85e-05	0.000308	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CTNNB1—cervical cancer	1.85e-05	0.000308	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—CTNNB1—cervical cancer	1.84e-05	0.000305	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—MTOR—cervical cancer	1.83e-05	0.000304	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CA9—cervical cancer	1.83e-05	0.000304	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CD4—cervical cancer	1.83e-05	0.000304	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FGFR3—cervical cancer	1.83e-05	0.000304	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CA9—cervical cancer	1.82e-05	0.000302	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FGFR3—cervical cancer	1.77e-05	0.000295	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—MTOR—cervical cancer	1.76e-05	0.000292	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD4—cervical cancer	1.75e-05	0.000292	CbGpPWpGaD
Erlotinib—EGFR—Disease—HES1—cervical cancer	1.74e-05	0.000289	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NOTCH1—cervical cancer	1.71e-05	0.000285	CbGpPWpGaD
Erlotinib—JAK3—Immune System—EGFR—cervical cancer	1.71e-05	0.000285	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—EGFR—cervical cancer	1.7e-05	0.000283	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CTNNB1—cervical cancer	1.62e-05	0.00027	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—STAT3—cervical cancer	1.61e-05	0.000268	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—STAT3—cervical cancer	1.6e-05	0.000266	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CA9—cervical cancer	1.59e-05	0.000265	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MTOR—cervical cancer	1.58e-05	0.000262	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	1.57e-05	0.000261	CbGpPWpGaD
Erlotinib—EGFR—Disease—MTHFR—cervical cancer	1.53e-05	0.000254	CbGpPWpGaD
Erlotinib—EGFR—Disease—TERT—cervical cancer	1.52e-05	0.000253	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CASP8—cervical cancer	1.52e-05	0.000252	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FGFR3—cervical cancer	1.52e-05	0.000252	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—EGFR—cervical cancer	1.5e-05	0.00025	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CA9—cervical cancer	1.5e-05	0.000249	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOTCH2—cervical cancer	1.49e-05	0.000247	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—EGFR—cervical cancer	1.47e-05	0.000244	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CASP3—cervical cancer	1.45e-05	0.000241	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—MTHFR—cervical cancer	1.41e-05	0.000234	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—cervical cancer	1.4e-05	0.000233	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGFR3—cervical cancer	1.4e-05	0.000233	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CTNNB1—cervical cancer	1.4e-05	0.000232	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	1.32e-05	0.000219	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—MTHFR—cervical cancer	1.31e-05	0.000218	CbGpPWpGaD
Erlotinib—EGFR—Disease—NOTCH1—cervical cancer	1.31e-05	0.000218	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CASP8—cervical cancer	1.3e-05	0.000215	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MTOR—cervical cancer	1.28e-05	0.000214	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CA9—cervical cancer	1.27e-05	0.000211	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MTOR—cervical cancer	1.25e-05	0.000207	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD4—cervical cancer	1.25e-05	0.000207	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—cervical cancer	1.23e-05	0.000205	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HES1—cervical cancer	1.22e-05	0.000203	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—STAT3—cervical cancer	1.22e-05	0.000202	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—MTHFR—cervical cancer	1.2e-05	0.000199	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CASP3—cervical cancer	1.18e-05	0.000196	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CTNNB1—cervical cancer	1.14e-05	0.000189	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EGFR—cervical cancer	1.11e-05	0.000184	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CTNNB1—cervical cancer	1.11e-05	0.000184	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TERT—cervical cancer	1.07e-05	0.000177	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MTOR—cervical cancer	1.07e-05	0.000177	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD4—cervical cancer	1.06e-05	0.000177	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—STAT3—cervical cancer	9.93e-06	0.000165	CbGpPWpGaD
Erlotinib—EGFR—Disease—MTOR—cervical cancer	9.84e-06	0.000164	CbGpPWpGaD
Erlotinib—EGFR—Disease—CD4—cervical cancer	9.83e-06	0.000163	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CA9—cervical cancer	9.81e-06	0.000163	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGFR3—cervical cancer	9.8e-06	0.000163	CbGpPWpGaD
Erlotinib—ABL1—Immune System—STAT3—cervical cancer	9.64e-06	0.00016	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CTNNB1—cervical cancer	9.45e-06	0.000157	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—cervical cancer	9.29e-06	0.000154	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOTCH1—cervical cancer	9.2e-06	0.000153	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EGFR—cervical cancer	9.02e-06	0.00015	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EGFR—cervical cancer	8.76e-06	0.000146	CbGpPWpGaD
Erlotinib—EGFR—Disease—CTNNB1—cervical cancer	8.73e-06	0.000145	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MTHFR—cervical cancer	8.57e-06	0.000142	CbGpPWpGaD
Erlotinib—EGFR—Immune System—STAT3—cervical cancer	8.24e-06	0.000137	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MTHFR—cervical cancer	8.09e-06	0.000135	CbGpPWpGaD
Erlotinib—EGFR—Disease—STAT3—cervical cancer	7.61e-06	0.000126	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—cervical cancer	7.58e-06	0.000126	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MTHFR—cervical cancer	7.42e-06	0.000123	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MTHFR—cervical cancer	7.38e-06	0.000123	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—cervical cancer	6.91e-06	0.000115	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MTOR—cervical cancer	6.89e-06	0.000115	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MTHFR—cervical cancer	6.46e-06	0.000107	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CASP3—cervical cancer	6.34e-06	0.000105	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CTNNB1—cervical cancer	6.11e-06	0.000102	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MTHFR—cervical cancer	6.09e-06	0.000101	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STAT3—cervical cancer	5.33e-06	8.86e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MTHFR—cervical cancer	5.16e-06	8.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—cervical cancer	4.07e-06	6.76e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTHFR—cervical cancer	3.98e-06	6.62e-05	CbGpPWpGaD
